Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024GlobeNewsWire • 10/21/24
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law FirmPRNewsWire • 10/01/24
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual ConferenceGlobeNewsWire • 09/30/24
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASHGlobeNewsWire • 09/09/24
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceGlobeNewsWire • 08/28/24
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)PRNewsWire • 08/23/24
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/09/24
Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 07/16/24
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the FirmGlobeNewsWire • 06/28/24
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmBusiness Wire • 06/25/24
FINAL AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit!Accesswire • 06/25/24
AKRO Today Is the Last Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud LawsuitPRNewsWire • 06/25/24
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)Business Wire • 06/24/24
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKROPRNewsWire • 06/24/24
AKRO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKROGlobeNewsWire • 06/24/24
INVESTOR DEADLINE TOMORROW: Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AKROAccesswire • 06/24/24
IMMINENT AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit!Accesswire • 06/24/24
TUESDAY DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AKROGlobeNewsWire • 06/23/24
Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)GlobeNewsWire • 06/23/24
Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)Accesswire • 06/22/24
AKRO Investors Have the Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud LawsuitPRNewsWire • 06/22/24
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud LawsuitPRNewsWire • 06/21/24
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero TherapeuticsGlobeNewsWire • 06/21/24
INVESTOR DEADLINE TUESDAY: Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AKROAccesswire • 06/21/24